GLP 1

Obese surgical patients can safely use GLP-1 therapy to reduce risk of complications, study concludes

August 13, 2025 / Research update / InnovateMed Author / GLP 1

by University of Birmingham edited by Sadie Harley, reviewed by Robert Egan Credit: Pixabay/CC0 Public Domain Overweight patients waiting for operations could safely use a particular type of weight-loss treatment to reduce the risk of surgical complications linked to their obesity, a new study reveals. The study highlights glucagon-like peptide-1 receptor agonists (GLP-1 RAs) as a promising medication […]

Obese surgical patients can safely use GLP-1 therapy to reduce risk of complications, study concludes Read More »

GLP-1 Users May Face Optic Nerve Damage Risk in First Year – pharmaceutical

August 3, 2025 / Clinical Practice / InnovateMed Author / GLP 1

TOPLINE: The use of GLP-1 receptor agonists, and particularly liraglutide, was associated with an increased risk of developing nonarteritic anterior ischemic optic neuropathy (NAION) during the first year of treatment, with the risk being most pronounced in individuals without type 2 diabetes (T2D) or obesity. METHODOLOGY: Researchers conducted a case-control study to examine the association

GLP-1 Users May Face Optic Nerve Damage Risk in First Year – pharmaceutical Read More »

Most GLP-1 Prescriptions Miss the Mark: Are Yours?

July 30, 2025 / Patient education / InnovateMed Author / GLP 1

GLP-1 receptor agonists, including semaglutide, are now widely used for weight loss, offering substantial weight reduction, improved metabolic health, and reduced cardiovascular risk. However, effective treatment involves more than simply prescribing drugs, and ongoing clinical oversight is crucial. Based on recommendations published in JAMA Internal Medicine, the following five tips can help physicians avoid common pitfalls

Most GLP-1 Prescriptions Miss the Mark: Are Yours? Read More »

Managing side effects: Nutrition and activity guidance issued for GLP-1 patients

July 29, 2025 / Clinical Practice / InnovateMed Author / GLP 1

by Justin Jackson, Phys.org edited by Sadie Harley, reviewed by Robert Egan Credit: Unsplash/CC0 Public Domain Harvard T.H. Chan School of Public Health suggests combining GLP-1 weight-loss medication with tailored nutrition and physical activity intervention is critical to mitigate side effects, preserve muscle, and prevent nutritional deficiencies. The growing use of GLP-1 and dual receptor agonists, such as

Managing side effects: Nutrition and activity guidance issued for GLP-1 patients Read More »

Which GLP-1 meds have the most side effects? Study of 60,000 Facebook posts gives answers

July 29, 2025 / Research update, Weight loss / InnovateMed Author / GLP 1

A deep dive into public Facebook posts uncovers the real-world side effect patterns of GLP-1 medications, revealing what users experience outside of clinical trials. Study: Harnessing Facebook to Investigate Real-World Mentions of Adverse Events of Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Medications: Observational Study of Facebook Posts From 2022 to 2024. Image Credit: zimmytws / Shutterstock In a

Which GLP-1 meds have the most side effects? Study of 60,000 Facebook posts gives answers Read More »

GLP-1 diabetes drugs likely trump metformin for curbing dementia risk in type 2 diabetes, study finds

July 23, 2025 / Research update, Weight loss / InnovateMed Author / GLP 1, metformin, type 1 diabetes

by British Medical Journal edited by Sadie Harley, reviewed by Andrew Zinin Metformin 500mg tablets. Credit: public domain GLP-1 receptor agonists, a class of drug used to treat type 2 diabetes, likely trump the widely prescribed metformin for curbing dementia risk in people with the condition, finds the largest study of its kind, published in the open access

GLP-1 diabetes drugs likely trump metformin for curbing dementia risk in type 2 diabetes, study finds Read More »

5 things doctors want you to know before you start taking a GLP-1

July 18, 2025 / Patient education / InnovateMed Author / GLP 1

People who take medications such as Ozempic should eat a diet high in protein and do regular resistance training, doctors say. July 15, 2025 By Teddy Amenabar Roughly 16 million American adults are taking GLP-1 medications. They are a major breakthrough for people to shed pounds and manage conditions such as Type 2 diabetes. However, doctors say

5 things doctors want you to know before you start taking a GLP-1 Read More »

How one elite rehab center is ‘obliterating’ all kinds of cravings with GLP-1s

July 14, 2025 / News update, Weight loss / InnovateMed Author / GLP 1

Rachel Wisniewski for STAT Ever since blockbuster weight loss medications burst on to the scene, GLP-1s have shown promise as not just a way to lose weight, but to revolutionize our understanding of desire. Early data showing the potential to treat addiction has been particularly exciting. But only a handful of clinical trials are underway, with several

How one elite rehab center is ‘obliterating’ all kinds of cravings with GLP-1s Read More »

7 Supplements to Take With Ozempic, Wegovy, and Other GLP-1-Related Medications

June 6, 2025 / Patient education / InnovateMed Author / GLP 1

Written by Alex Evans, PharmD, MBA | Reviewed by Patricia Pinto-Garcia, MD, MPH Published on April 29, 2025 Key takeaways: We don’t know for sure how GLP-1-related medications such as Ozempic (semaglutide) affect nutrient levels in your body. But there’s some evidence that they may reduce the absorption of iron while you’re using them. GLP-1-related medications can reduce

7 Supplements to Take With Ozempic, Wegovy, and Other GLP-1-Related Medications Read More »

Q&A: Long-term success of GLP-1 therapies hinges on more than just a prescription

June 5, 2025 / Clinical Practice / InnovateMed Author / GLP 1

by Tufts University edited by Lisa Lock, reviewed by Robert Egan Credit: The American Journal of Clinical Nutrition (2025). DOI: 10.1016/j.ajcnut.2025.04.023 GLP-1 (glucagon-like peptide-1) therapies can be powerful tools in managing obesity, with patients taking these medications seeing weight reductions of 5%–18% in clinical trials, along with increased metabolism and benefits to their overall heart health. However, GLP-1s can

Q&A: Long-term success of GLP-1 therapies hinges on more than just a prescription Read More »